Resistance Training for Prostate Cancer
Trial Summary
What is the purpose of this trial?
Prostate cancer and its treatment are associated with many long-term adverse effects including cancer-related cognitive impairment. Specifically, androgen deprivation therapy has been shown to negatively impact cognitive function. Combined aerobic and resistance training has been shown to improve cognitive function in men treated with androgen deprivation therapy, but limited research has observed its impact into survivorship. Additionally, existing study designs are limited to supervised, combined aerobic and resistance training interventions. Remotely-delivered resistance training programs could enhance exercise participation by overcoming commonly reported barriers in men living with and beyond prostate cancer such as transportation, distance to facility, and timing of programs. Alongside the needs to address cancer-related cognitive impairments due to androgen deprivation therapy, resistance training may serve to manage functional deficits, losses in bone mineral density and muscle mass and increases in cardiometabolic risk factors. This study will assess the feasibility of an 8-week remotely-delivered resistance training program to improve cognitive function in men living with and beyond prostate cancer who have a history of androgen deprivation therapy treatment.
Research Team
Eligibility Criteria
This trial is for men who have or had prostate cancer and were treated with androgen deprivation therapy. It's designed to see if working out at home with resistance training can help improve their thinking skills, which may be affected by their treatment.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Remotely-Delivered Resistance Training Program (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Toronto
Lead Sponsor
Allison Brown
University of Toronto
Chief Medical Officer
PhD in Chemical Engineering from the University of Toronto
Michael Sefton
University of Toronto
Chief Executive Officer since 2017
PhD in Chemical Engineering from the University of Toronto and MIT